Physician profile
Esther Schlesinger
NPI 1447341722
$7,225.16
in general payments reported to CMS, 2019-2025
14 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $386 · 2021: $1,068 · 2022: $1,738 · 2023: $1,707 · 2024: $1,088 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,319.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,487.04 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,402.06 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,388.12 | 2019-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $994.39 | 2019-2024 | Uzedy, Austedo Xr, Austedo |
| Abbvie INC. | $703.77 | 2021-2023 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $464.13 | 2020-2023 | |
| Alkermes, INC. | $285.80 | 2019-2025 | Aristada, Aristada Initio, Lybalvi |
| Axsome Therapeutics, INC. | $122.04 | 2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $112.24 | 2019-2021 | |
| Allergan, INC. | $85.22 | 2019-2020 | |
| Indivior INC. | $83.27 | 2021-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $55.00 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $27.26 | 2022 | |
| Noven Therapeutics, LLC | $14.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Schlesinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.